Skip to main content
Premium Trial:

Request an Annual Quote

Norrie Russell, Tim Germann, Anthony Altig, Gran Ando, Gordon Wasserman, and John Bergeron


Norrie Russell has joined Invitrogen as vice president and general manager of its functional genomics strategic business unit, the company said last week. Most recently, he was president and CEO of Aviva Biosciences. Prior to that, he was president and CEO of Lynx Therapeutics. Russell holds a PhD in physiology from Glasgow University in Scotland.

Tim Germann has assumed the newly created position of vice president of sales and marketing for US Genomics, the company said this week. Prior to his new post, he was the northeast sales manager for Affymetrix. Before that, he held sales or management positions at Stratagene, Genometrix, Incyte Genomics, and Molecular Devices. Germann holds a BS degree in business management from Brigham Young University.

Anthony Altig has become CFO and senior vice president of finance of Diversa, the company said this week. He joins Diversa from Maxim Pharmaceuticals, where he was CFO. Altig holds a degree from the University of Hawaii.

Göran Ando has been appointed to the board of directors of Enzon Pharmaceuticals, the company said on this week. Prior to becoming CEO of Celltech in 2003, he held a number of senior R&D posts at Pharmacia. Ando holds an MD from Linkoping University in Sweden.

Gordon Wasserman has filled a newly created slot on the board of directors of Orchid BioSciences, the company said this week. He is the CEO of his own consulting firm that specializes in the management of police agencies, particularly scientific and technological support services. Wasserman served as assistant under secretary of state for police science and technology in the UK government for more than 10 years. He has also been an adviser to the police commissioners of New York City and Philadelphia; the chiefs of police of Miami; Hartford and other US cities; the US Department of Justice; and several other national governments. Wasserman holds BA and MA degrees from Oxford University and a BA from McGill University.

John Bergeron will receive the McLaughlin Medal from the Royal Society of Canada, the Canadian Academy of the Sciences and Humanities, at the society’s awards banquet on Nov. 20. He is a professor and chair of anatomy and cell biology at McGill University and director of the Montreal Proteomics Network. He is also the current president of HUPO. Bergeron holds a PhD from Oxford University and an undergraduate degree in biochemistry from McGill University.


Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.